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http://dx.doi.org/10.1016/j.ccr.2014.04.024SUMMARYRecurrent mutations in histone-modifying enzymes imply key roles in tumorigenesis, yet their functional rele-
vance is largely unknown. Here, we show that JARID1B, encoding a histone H3 lysine 4 (H3K4) demethylase,
is frequently amplified and overexpressed in luminal breast tumors and a somatic mutation in a basal-like
breast cancer results in the gain of unique chromatin binding and luminal expression and splicing patterns.
Downregulation of JARID1B in luminal cells induces basal genes expression and growth arrest, which is
rescued by TGFb pathway inhibitors. Integrated JARID1B chromatin binding, H3K4methylation, and expres-
sion profiles suggest a key function for JARID1B in luminal cell-specific expression programs. High luminal
JARID1B activity is associated with poor outcome in patients with hormone receptor-positive breast tumors.Significance
Transcriptional regulators are recurrently mutated in breast c
programs in tumorigenesis. Here, we show that JARID1B is
luminal and basal cell-specific expression programs. A hetero
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commonly mutated in breast tumors and that it modulates
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-overlapping, compared to nonoverlapping, sites. Our data
at may represent a target in luminal breast tumors. However,
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Histone lysine methylation is important for chromatin organiza-
tion and the regulation of gene expression (Dawson and Kouzar-
ides, 2012). Systemic sequencing of human cancer genomes
identified numerous alterations in genes encoding histone-modi-
fying enzymes, including somatic mutations of KDM6A, KDM5C,
and KDM5B (also called JARID1B, PLU-1), in multiple cancer
types (You and Jones, 2012). However, the functional and clin-
ical relevance of these mutations are still poorly understood.
In breast cancer, genes encoding transcriptional regulators
(e.g., FOXA1, GATA3) are among the most frequently mutated
genes, suggesting a key role for perturbed epigenetic programs
in tumorigenesis (Polyak and Metzger Filho, 2012). Several of
these genes are mutated in a breast tumor subtype-specific
manner (TCGA, 2012). Breast tumors are classified based on
the expression of estrogen receptor (ER), progesterone receptor
(PR), and HER2 into ER+, HER2+, and ERPRHER2 (triple-
negative breast cancer [TNBC]) disease. Based on gene expres-
sion profiles, breast tumors are characterized as luminal or
basal-like (Perou et al., 2000; Sørlie et al., 2001). HER2+ and
ER+ tumors typically have luminal features, whereas TNBCs
show significant, but not complete, overlap with the basal-like
subtype. In general, many more recurrent mutations are present
in luminal than in basal-like breast tumors (Polyak and Metzger
Filho, 2012). The high frequency of mutations in GATA3 and
FOXA1 transcription factors with essential roles in luminal
epithelial differentiation (Bernardo et al., 2010; Kouros-Mehr
et al., 2006) in luminal breast tumors suggests that perturbed
differentiation programs are important for tumor development.
Increasing evidence indicates that histone methyltransferases
(HMTs) and demethylases (HDMs) play key roles in regulating
cellular differentiation states. KDM5B, which encodes the his-
tone H3 lysine4 (H3K4) demethylase JARID1B (Christensen
et al., 2007; Iwase et al., 2007; Yamane et al., 2007), was first
identified as a gene whose expression was reversibly regulated
by HER2 signaling in breast cancer cells (Lu et al., 1999). Over-
expression of JARID1B in HeLa cells results in loss of tri-, di-,
and monomethyl H3K4 but does not affect H3K9, H3K27, or
H3K36 methylation.
JARID1B is overexpressed in prostate carcinomas, where it
associates with the androgen receptor and regulates its tran-
scriptional activity (Xiang et al., 2007). Overexpression and tumor
growth-promoting effects of JARID1B have also been described
in bladder and lung cancers (Hayami et al., 2010). In contrast, the
expression of JARID1B is downregulated in melanoma, where it
has been implicated as a tumor suppressor inhibiting cell prolif-
eration in an RB-dependent manner (Roesch et al., 2006, 2008).
However, JARID1B also plays a role in melanoma tumor mainte-
nance and in metastatic progression based on xenotransplant
assays in immunodeficient mice (Roesch et al., 2010).
JARID1B regulates the proliferation and differentiation of em-
bryonic stem cells (ESCs) (Dey et al., 2008; Frankenberg et al.,
2007; Kidder et al., 2013; Schmitz et al., 2011; Xie et al., 2011;
Yamane et al., 2007; You and Jones, 2012), and it is involved
in murine mammary gland development (Catchpole et al.,
2011). JARID1B overexpression in ESCs decreases the expres-
sion of differentiated cell-specific genes and increases prolif-
eration (Dey et al., 2008). The targeting of key transcriptionalregulators of progenitor cell function may also play a role in
JARID1B’s tumor-promoting effects, a hypothesis that has not
been tested experimentally. Despite the importance of JARID1B
in normal development and in tumorigenesis, its mechanism of
action is still poorly defined.
RESULTS
JARID1B Is Amplified and Overexpressed in Breast
Tumors
We identified JARID1B as a gene with common copy number
gain based on our single nucleotide polymorphism (SNP) array
analysis of breast tumors and cancer cell lines (Nikolsky et al.,
2008), which we also confirmed by quantitative PCR (qPCR)
and fluorescent in situ hybridization (FISH) (Figure 1A; Figure S1A
available online; data not shown). Analysis of the METABRIC
data set (Curtis et al., 2012) showed that JARID1B copy number
gain is associated with increased transcript levels (Figure 1B),
especially in luminal subtypes (compare Figures 1C and S1B).
JARID1B mRNA levels are also the highest in luminal A and
HER2+ tumors both when using the PAM50 (Parker et al.,
2009) and the IC10 (Curtis et al., 2012) classification (Figures
1D and 1E) and somewhat higher in ER+ than in ER cases (Fig-
ure S1C). JARID1B protein levels displayed a similar trend in
breast cancer cell lines (Figure S1D).
Loss of JARID1B Inhibits Breast Cancer Cell Growth
To investigate the functional relevance of JARID1B overexpres-
sion in breast cancer, first we performed a lentiviral small hairpin
RNA (shRNA) screen for cellular viability in a panel of luminal
and basal-like breast cancer cell lines. In both the primary and
secondary screens, shRNAs against JARID1B had the most pro-
nounced growth inhibitory effect in ER+ luminal breast cancer
cells (MCF7 and T-47D) based on the significance of decrease
in viable cells (i.e., Z score in the primary and percent decrease
of viability in the secondary screen) and the number of indepen-
dent shRNA clones that were hits in these assays (Figures 1F,
S1E, and S1F). Similar results were obtained using JARID1B-
targeting small interfering RNAs (siRNAs) (Figures S1G–S1I),
and the decrease in cell viability was rescued by the exogenous
expression of siRNA-resistant JARID1B cDNAs (Figures S1J and
S1K). We did not detect significant apoptosis in any of the cell
lines after siJARID1B transfection, consistent with prior reports
(Yamane et al., 2007). The downregulation of JARID1B did not
affect the protein levels of the closely related JARID1A, and it
only slightly increased global histone H3K4me3 levels in the
MCF7 and T-47D luminal breast cancer cell lines with no
obvious change in H3K4me1/2 or H3K27me3 (Figures S1L
and S1M). These results support the hypothesis that JARID1B
is a target of the 1q32 amplicon and suggested that JARID1B
function might particularly be important in ER+ luminal breast
cancer cells.
Loss of JARID1B-Induced Gene Expression Changes
To further explore JARID1B function, we performed RNA-seq of
luminal and basal-like breast cancer cell lines transfected with
control or JARID1B-targeting siRNAs and identified genes with
significant expression changes. Basal-like and luminal breast
cancer cell lines clustered together based on RNA-seq profilesCancer Cell 25, 762–777, June 16, 2014 ª2014 Elsevier Inc. 763
Figure 1. JARID1B Is a Luminal Lineage-Specific Oncogene in Breast Cancer
(A) A representative image of metaphase FISH analysis of MCF7 luminal ER+ breast cancer cells using JARID1B bacterial artificial chromosome (green) and
chromosome 1 centromeric (red) probes.
(B and C) Correlation between JARID1B gene expression (mRNA) and copy number in all tumors (n = 1,944) (B) and luminal A (n = 711) subset (C) based on the
analysis of breast tumors in the METABRIC data set. r indicates linear correlation coefficient.
(D and E) Associations between JARID1B expression and PAM50 (n = 1,944) (D) and ten different breast tumor (integrative clusters, IC10) (n = 1,980) (E) subtypes
in the METABRIC data set. Small colored rectangles in (E) indicate the composition of IC10 clusters according to PAM50 subtype. The differences in JARID1B
mRNA levels among breast tumor subtypes are statistically significant (see the Supplemental Experimental Procedures for details).
(F) shRNA clones identified as hits in the cellular viability screen in the indicated cell lines. Colors indicate luminal (blue), basal-like (red), and HER2+ (pink) breast
cell lines, respectively. Numbers indicate fraction (%) of viable cells compared to control. Red shading indicates growth inhibition above cutoff (75%).
See also Figure S1.
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JARID1B and Luminal Genes in Breast Cancerwith the exception of the JARID1B mutant HCC2157 basal-like
line that clustered with luminal lines (Figure 2A). The cell lines
showed variable number of genes with significantly altered
expression after siJARID1B transfection (Figures S2A and764 Cancer Cell 25, 762–777, June 16, 2014 ª2014 Elsevier Inc.S2B); thus, we selected the top 200 differentially expressed
genes in each cell line for comparison (Table S1). Clustering of
the samples based on the expression of all significantly (R1.5
robust fold-change estimate; Feng et al., 2012) differentially
Figure 2. The Effect of JARID1B on Gene Expression Patterns
(A and B) Hierarchical clustering of breast cancer cell lines by log2(RPKM) based on similarities in the expression pattern of all transcripts (A) and byGFold value of
the top 200 genes differentially expressed after siJARID1B (B). Gene expression index is measured by the logarithm of gene’s reads per kilo base per million
(RPKM) value. The genes chosen for clustering in (B) are the union of top 200 differentially expressed genes after siJARID1B transfection in each cell line.
(C) Measurement of expression changes for selected genes by quantitative RT-PCR.
(D) Changes in the expression of basal/stem cell-related genes in siJARID1B-transfected MCF7 cells.
(E) Clustering of breast cancer gene expression data frommultiple different cohorts based on the top 200 differentially expressed genes with JARID1B promoter
binding in theMCF7 cell line following transfection of siJARID1B. Change of expression level inMCF7 after siJARID1B transfection is indicated to the left (Cell-line
expr), followed by the difference between luminal A and basal-like samples from all cohorts (Basal-lumA).
(F and G) Rescue from JARID1B siRNA-induced growth inhibition by treatment with LY2109761 (F) or by downregulation of SMAD4 or TGFBR2 by siRNAs (G).
In all panels, *p < 0.05; **p < 0.001; error bars mark SD. See also Figure S2 and Table S1.
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JARID1B and Luminal Genes in Breast Cancerexpressed transcripts (Figure S2A) or using the union of top 200
differentially expressed genes (Figure 2B) showed some luminal
and basal differences. In luminal cells, more genes were up than
downregulated following siJARID1B transfection, whereas the
opposite was observed in basal-like cells (Figure S2B). The dif-
ferences in expression levels were also confirmed by quantita-
tive RT-PCR for selected genes in MCF7 cells (Figure 2C).
TGFb Signaling in JARID1B Loss-Mediated Growth
Arrest
To explore the functional relevance of gene expression changes
following downregulation of JARID1B, we performed network
and pathway analyses of the top 200 differentially expressed
genes using the Metacore suit (Bessarabova et al., 2011). This
approach identified a prominent upregulation of basal/stem
cell genes in siJARID1B-transfected luminal cells (Figures 2D,
2E, and S2C) and significant enrichment for the TGFb signaling
pathway (Figure S2D). Correlating with this, the top 200 differ-
entially expressed genes in siJARID1B-transfected MCF7 cells
showed distinct patterns of expression in luminal and basal-
like primary breast tumors (Figures 2E and S2C), with the up
genes in general having higher expression in basal-like tumors,
demonstrating the physiologic relevance of these gene signa-
tures in patient samples. Interestingly, in basal-like cells enrich-
ment for the TGFb signaling pathwaywas observed for the genes
downregulated after siJARID1B transfection (Figure S2D), again
suggesting luminal-basal differences in JARID1B’s function.
To further investigate the role of TGFb signaling in JARID1B
loss-mediated growth arrest, we first analyzed phosphoSMAD2,
a key downstream target of TGFb receptor kinases, and found
increased levels in siJARID1B-transfected MCF7 cells (Fig-
ure S2E). To determine whether the activation of TGFb signaling
is required for JARID1B loss-mediated growth arrest, we down-
regulated key components of the TGFb pathway (i.e., SMAD4
and TGFBR2) by siRNAs (Figure S2F) or inhibited TGFb receptor
kinase activity using a small molecule inhibitor (SMI). Treatment
of MCF7 and T-47D luminal breast cancer cells with a trans-
forming growth factor-beta receptor (TGFBR) kinase inhibitor
(LY2109761) rescued the siJARID1B-induced growth arrest in
a dose-dependent manner, whereas no effect was seen in
SUM159PT basal-like cells (Figure 2F; data not shown). Downre-
gulation of SMAD4 or TGFBR2 by siRNAs had similar effects
(Figure 2G; data not shown). These results suggest that JARID1B
expression in luminal breast cancer cells is required for theFigure 3. JARID1B Binding Patterns in Breast Tumor Subtypes
(A) Heatmap and hierarchical clustering of JARID1B genomic binding peaks (±3 k
lines. The JARID1B mutant HCC2157 cell line is marked with an asterisk, and th
(B) Pie chart of top 10k JARID1B binding peaks location in relation to its distanc
(C) Hierarchical clustering of breast cancer cell lines considering JARID1B bind
regions. Both clusters are significant in terms of p value (using pvclus).
(D) Ratio of H3K4me3/H3K4me2 signal at JARID1B peak regions in MCF7 cel
coefficient of siJARID1B and siControl H3K4me3 signals in JARID1B region (cor
(E) Union of JARID1B, H3K4me3, H3K4me2, and H3K4me1 binding peaks in MC
(F) Examples of peak maps and ChIP-qPCR for selected genes. Black bar and a
(G) Examples of H3K4me3 ChIP-qPCR for selected genes in control and siJARID
(H) Heatmap of JARID1B signal around TSS of all RefSeq genes in breast cancer
clustering (k = 2) is applied to all genes promoters. Histone marks and gene expre
Gene expression value is the logarithm of RPKM for each gene.
In all panels, *p < 0.05; **p < 0.001; error bars mark SD. See also Figure S3 andrepression of basal cell-specific genes, including those impor-
tant for TGFb signaling, and the loss of this repression following
decreased JARID1B leads to growth arrest. In contrast, in basal-
like breast cancer cells, JARID1B loss leads to decreased TGFb
pathway activity, but this may not play a role in JARID1B loss-
mediated growth arrest in this cell type.
Genomic Targets of JARID1B
To identify the genomic targets of JARID1B, we performed chro-
matin immunoprecipitation sequencing (ChIP-seq) in luminal
and basal-like breast cancer cells. ChIP was optimized and the
specificity of the JARID1B antibody was validated by ChIP-
qPCR, which showed significant decrease in signal at known
JARID1B-binding regions in siJARID1B-expressing MCF7 cells
(Figures S3A–S3C). The number of JARID1Bpeaks varied among
cell lines; thus, we used the top 10,000 peaks in each cell line for
comparisons among samples. Clustering of the samples based
on JARID1B peaks showed luminal and basal patterns (Fig-
ure 3A). Interestingly, the JARID1B mutant HCC2157 basal-like
cell line showed higher relatedness to luminal cells and had
numerous unique peaks. The number and distribution of
JARID1B peaks relative to transcription start site (TSS) varied
among cell lines with luminal cells in general having more pro-
moter and basal-like cells having more nonpromoter peaks (Fig-
ure 3B), and intriguingly >90% of the 9,891 HCC2157 unique
peaks were located in nonpromoter regions (Table S2). Clus-
tering of the samples using promoter and nonpromoter peaks
demonstrated that luminal-basal differences in JARID1B binding
are more significant at nonpromoter regions and again high-
lighted the uniqueness of HCC2157 cells (Figure 3C).
JARID1B Binding Pattern Overlaps with H3K4me3 and
Active Genes
JARID1B is a histoneH3K4demethylase andbasedon in vitro as-
says it can demethylate all three H3K4 methylated forms (i.e.,
mono-, di-, and trimethyl) albeit with varying efficiency and with
the highest affinity for H3K4me3 (Christensen et al., 2007; Iwase
et al., 2007;Kristensenet al., 2012;Yamaneet al., 2007). Thus,we
investigatedwhether JARID1Bchromatin binding andchanges in
JARID1B levels influence H3K4 methylation patterns in breast
cancer cells. Correlating with its HDM function, we detected
increased H3K4me3/me2 signal ratios following downregula-
tion of JARID1B in MCF7 cells (Figure 3D). However, despite its
H3K4me3/2 HDM activity, we found that JARID1B bindingb around peak summit) in luminal (blue) and basal-like (red) breast cancer cell
e green rectangle highlights unique peaks.
e from TSS.
ing signals only in nonpromoter (left panel) and only in promoter (right panel)
ls transfected with siControl and siJARID1B. p value for Pearson correlation
relation value = 0.98999, n = 91,992, p value = 0).
F7 and SUM159PT cell lines.
–f indicate primers used for qPCR in the right panel.
1B-transfected cells untreated or treated with LY2109761.
cell lines. Each row is a gene promoter region centered around TSS. K-mean
ssion columns are plotted according to the order of genes from the clustering.
Table S2.
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luminal and basal-like breast cancer cells (Figures 3E and S3D),
potentially because of the high affinity of its PHD domains to
H3K4me3 as reported for JARID1A (Wang et al., 2009). We vali-
dated increased H3K4me3/me2 levels after siJARID1B expres-
sion for several genes with clearly overlapping JARID1B and
H3K4me3/me2 peaks in their promoter region and increased
expression in siJARID1B-transfected MCF7 cells (Figures 3F
and 3G; Figures S3B and S3C). Interestingly, the increase in
H3K4me3 signal in siJARID1B-transfected cells was abrogated
by treatment with a TGFBR kinase inhibitor (Figure 3G).
H3K4me3 and H3K4me2 mark transcriptionally active genes
(Ram et al., 2011; Zhang and Pugh, 2011). In line with this, genes
with JARID1B promoter binding were highly expressed in all cell
lines analyzed (Figure 3H). These data suggest that JARID1B
chromatin binding by itself may not be sufficient for HDM func-
tion or that JARID1B is fine-tuning the levels of genes already
destined to be expressed in the cells. To further explore these
associations, we analyzed JARID1B binding and H3K4me3/
me2-enrichment patterns of genes up- or downregulated in
siJARID1B-transfected MCF7 cells. We found that the pro-
moter region of the differentially expressed genes was signifi-
cantly enriched for JARID1B binding and also for H3K4me3
and H3K4me2 (Figure 4A), indicating a clear and strong associ-
ation between JARID1B promoter binding and downstream
gene expression changes in siJARID1B-transfected cells.
To investigate the sequence-specificity of JARID1B binding,
we performed motif analysis of JARID1B binding sites and iden-
tified highly CG-rich sequences (Figures 4B andS4A), confirming
the results of in vitro binding assays (Scibetta et al., 2007). The
presence of CpG nucleotides in these consensus motifs raised
the possibility that JARID1B binding might be influenced by
DNA methylation. To explore this, we analyzed potential associ-
ations between DNA methylation and JARID1B targets (see the
Supplemental Experimental Procedures for details). Baseline
DNA methylation was higher in genes that were upregulated in
siJARID-transfected luminal MCF7 and T-47D cells, whereas
the opposite was observed in some basal-like cells (Figure 4C).
However, these differences might simply reflect the association
of JARID1B with H3K4m3/me2-enriched regions as unmethy-
lated H3K4 has been linked to de novo DNA methylation (Ooi
et al., 2007). Correlating with this, JARID1B-binding sites had
lower levels of DNAmethylation than did other regions analyzed,
and this was also associated with differences in H3K4me3
enrichment (Figures S4B andS4C). Thus, DNAmethylationmight
influence JARID1B binding and its effect on gene expression, but
delineating these relationships will require further studies.
JARID1B Binding Is Enriched in Luminal-High Genes
To further investigate JARID1B chromatin binding patterns, we
analyzed associations between JARID1B binding and genes
differentially expressed between luminal and basal-like breast
cancer cells. Despite its overall binding to actively transcribed
genes in all cell types, JARID1B showed significant enrichment
in the promoter and enhancer regions of luminal-high genes in
luminal cells with a much less pronounced pattern observed
for basal-high genes in basal cells (Figure 4D). These results
imply potential cooperation between JARID1B and luminal line-
age-specific transcription factors (TFs). We investigated this768 Cancer Cell 25, 762–777, June 16, 2014 ª2014 Elsevier Inc.by integrating ChIP-seq data for such TFs in breast cancer cells
with our results.We found that luminal-high genes in luminal cells
were enriched for genomic targets of ER, GATA3, FOXA1, and
TFAP2C transcription factors with known roles in luminal differ-
entiation (Kouros-Mehr et al., 2008; Siegel andMuller, 2010) (Fig-
ure 4D). We also found a significant overlap between JARID1B
promoter binding genes and genes differentially expressed
3 hr after estradiol treatment in MCF7 cells (Figure S4D). How-
ever, because JARID1B peaks are enriched in highly expressed
genes in luminal cells and ER is a key transcriptional activator in
MCF7 cells, seeing a significant overlap is not unexpected. Thus,
this observation by itself does not prove a functionally relevant
link between JARID1B and ER targets.
In contrast, promoters and enhancers of basal-high genes
with JARID1B binding did not show enrichment for any TFs
with available ChIP-seq data (data not shown). Thus, the com-
bined activation of luminal-specific and repression of basal-spe-
cific genes might be required for the establishment of luminal
cell-specific gene expression programs and associated pheno-
types, whereas basal-specific patterns might represent default
states or regulated by not-yet characterized TFs.
Clinical Relevance of JARID1B Activity in Breast Cancer
To investigate the clinical relevance of JARID1B copy number
gain and overexpression in breast cancer, we analyzed molecu-
lar data from 1,980 breast carcinomas (the METABRIC cohort)
(Curtis et al., 2012). JARID1B expression level varied with
respect to PAM50 subtype and the ten integrative clusters (Fig-
ures 1D and 1E). To explore the activity of JARID1B in a more
comprehensive manner, we used PARADIGM (Vaske et al.,
2010) to create signatures mirroring JARID1B activity in MCF7
and SUM159PT cell lines based on gene expression, copy-
number, and JARID1B ChIP-seq data (MCF7 and SUM159PT-
index). The two JARID1B activity indexes were calculated for
each METABRIC sample by extracting gene expression and
copy number features included in the signature. For each index,
samples were split into three groups; negative, zero, or positive
JARID1B activity, with distinct clinicopathological features
(Table S3). The three JARID1B MCF7-index groups showed
different outcomes in which patients with ER+ tumors and a pos-
itive JARID1B activity score had a shorter disease-specific sur-
vival than did patients with ER+ tumors and negative JARID1B
activity (Figure 5A). Positive JARID1B activity had a hazard ratio
of 1.9 (95% CI 1.1–3.3, p = 0.029) in ER+ tumors compared to
negative activity after correcting for known prognostic covari-
ates in a Cox regression model (Table S4). The differences in
survival depending on JARID1B activity remained significant
in ER+ tumors treated with endocrine therapy alone (Figure 5A).
The JARID1B SUM159PT-index also showed a significant
difference in survival for patients with ER+ tumors, but here
zero activity indicated worse prognosis (Figure 5B). These data
again highlight that JARID1B activity is distinct between luminal
and basal breast cancer cells and that positive luminal JARID1B
activity is associated with worse outcomes in luminal ER+
tumors, implying oncogenic function.
JARID1B and CTCF Interaction
To identify potential JARID1B-interacting proteins that may
modulate its function in breast cancer cells, we conducted a
Figure 4. Integrated View of JARID1B Activity
(A) Integrated view of siJARID1B differential genes in MCF7 cells and their association with JARID1B, H3K4me2, and H3K4me3 promoter binding signal. Each
column is a gene, ranking by the differential gene GFold value comparing siJARID1B with siControl.
(B) Two of the highest scoring consensus sequence motifs in top 5,000 JARID1B peaks in MCF7 cells. Z scores = 87.5043 (top) and 87.3197 (bottom),
p value = 130.
(C) Box plots depict average beta values of DNA methylation for all genes and genes up or downregulated after expression of siJARID1B. *** marks p < 0.001;
detailed statistical analysis is included in the Supplemental Experimental Procedures.
(D) Integrated view of differential gene expression (GFold > 1, 947 genes), JARID1B, FOXA1, GATA3, ER, and TFAP2C binding at promoters and enhancers in
luminal (MCF7 and T-47D combined), and basal (SUM159PT andMDA-MB-231 combined) breast cancer cell lines. Wilcoxon test for basal and luminal JARID1B
signal in promoter (W = 430,557,937, p value < 2.216) and in enhancer (W = 511,285,604, p value < 2. 3 1016).
See also Figure S4.
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identified CTCF as the top scoring factor (Z score 81.1077,
10*log(pval): 690.7755279), both in luminal and basal breast
cancer cells (Table S5). We verified overlap with CTCF byChIP-seq in both cell lines (Figures 6A and 6B) using ENCODE
data for MCF7 (Lee et al., 2012) and our data in SUM159PT cells.
Overall, a relatively higher fraction of JARID1B overlaps with
CTCF in SUM159PT compared to MCF7 cells, both in promoterCancer Cell 25, 762–777, June 16, 2014 ª2014 Elsevier Inc. 769
Figure 5. Clinical Relevance of JARID1B Activity in Breast Tumors
Associations between MCF7 (A) and SUM159PT (B) PARADIGM JARID1B activity indices and disease-specific survival in breast cancer patients with ER+ and
ER tumors. Red, green, and blue colors indicate positive, negative, and zero JARID1B activity. ‘‘End treat’’ indicates endocrine treatment only.
See also Tables S3 and S4.
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JARID1B and Luminal Genes in Breast Cancerand nonpromoter regions (Figure 6C). However, in MCF7 cells
the ratio of overlapping sites was much smaller in promoter
compared to nonpromoter regions, whereas no such difference
was detected in SUM159PT cells. Because the binding of CTCF
is inhibited by DNAmethylation (Shukla et al., 2011), we analyzed
the level of DNA methylation of CTCF binding sites in relation to
transcription start site (TSS) and JARID1B binding. CTCF binding
sites had low level of DNA methylation, which was even lower
at CTCF-JARID1B overlapping sites (Figure S5A). These differ-
ences were significant in both MCF7 and SUM159 cells but
were more pronounced at nonpromoters in MCF7 cells.
To determine if the overlap of JARID1B andCTCF binding sites
may indicate that the two proteins are present in the same com-
plex, we performed JARID1B immunoprecipitation followed by
CTCF immunoblot in a panel of breast cancer cell lines. We de-
tected variable levels of CTCF protein in JARID1B immunopre-
cipitates in all cell lines tested, except in SUM185PE, suggesting
that the two proteins may interact in most breast cancer cells
(Figure 6D).
To explore potential associations between JARID1B-CTCF
and H3K4 methylation status, we analyzed H3K4me3 signal in
relation to JARID1B-CTCF overlap. The level H3K4me3 signal
at sites of JARID1B-CTCF overlap was significantly lower in
MCF7 luminal cells (Figure S5B), and this was most pronounced
in promoters (Figure 6E). In line with this, we detected signifi-
cantly (p value < 2.216, Wilcoxon test) stronger JARID1B
and weaker CTCF signal at promoters in MCF7 luminal cells770 Cancer Cell 25, 762–777, June 16, 2014 ª2014 Elsevier Inc.compared to the SUM159PT basal-like cells (Figure 6F). The
nonoverlapping sites had higher H3K4me3 signal in MCF7
cells, whereas in SUM159PT cells even these sites showed
somewhat lower values, implying that the JARID1B-CTCF inter-
action may have a more pronounced effect in luminal compared
to basal breast cancer cells. These observations are intriguing
in light of recurrent CTCF mutations in ER+ breast cancer (Ellis
et al., 2012; TCGA 2012), implying a subtype-specific role in
tumorigenesis.
CTCF is known to havemany different biological functions and
can have opposing effects on gene expression depending on the
location of its binding site relative to TSS (Filippova, 2008; Fior-
entino andGiordano, 2012). Thus, to further explore the potential
relevance of CTCF-JARID1B interaction in luminal breast cancer
cells, we analyzed JARID1B chromatin binding and gene expres-
sion patterns in MCF7 cells following transfection with siCTCF.
JARID1B peak signal significantly decreased in siCTCF-trans-
fected cells (Figure 6G), and this decrease was more significant
(p value < 2.216 Wilcox test) in the JARID1B-CTCF overlapping
versus nonoverlapping sites in the promoter regions, whereas
the opposite was observed in nonpromoters (Figure S5C). Coin-
cidentally, with a decrease in CTCF and JARID1Bpromoter bind-
ing, we observed an increase in global H3K4me3 levels in MCF7
cells (Figure S5D). In contrast, in SUM185PT cells that were
negative for JARID1B-CTCF complexes by immunoprecipita-
tion, H3K4me3 decreased after siCTCF (Figure S5D), and this
was accompanied by increased JARID1B chromatin binding in
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results imply that CTCF may modulate JARID1B’s chromatin
binding function and HDM activity. However, many of these
associations might be due to global chromatin changes induced
by decreased CTCF levels and may not reflect the functional
relevance of CTCF-JARID1B interaction; dissecting the underly-
ing mechanisms requires further studies.
JARID1B Mutant with Luminal Gain of Function
Lastly, we investigated the potential functional relevance of
the K1435R JARID1B heterozygous missense mutation in the
HCC2157 basal-like breast cancer cell line (Figure 7A). Gene
expression and JARID1B ChIP-seq data revealed patterns
unique to HCC2157 cells that made it more similar to luminal
cells (Figures 2A and 3A), although this cell line is ERPRHER2
and classified as a basal-like breast cancer. Indeed, many of
the genes associated with HCC2157-unique JARID1B peaks
showed high expression in luminal breast tumors and cell lines
(Figures 7B and 7C). The SPDEF transcription factor with known
luminal functions was among the HCC2157-unique JARID1B
peaks, and both SPEDF and its targets showed elevated levels
in HCC2157 cells (Table S2). These data imply a gain of JARID1B
binding to luminal-specific genes leading to their increased
expression in this basal-like breast cancer cell line potentially
due to the JARID1B mutation. To test this experimentally, we
exogenously expressed Myc epitope-tagged wild-type (WT)
and mutant JARID1B in SUM159PT basal breast cancer cells
and assessed JARID1B binding and gene expression patterns.
We found that the K1435R mutant displayed greater enrichment
for HCC2157-unique JARID1B peaks (Figure 7D), and this was
accompanied with modest differences in the expression of
some genes nearest to these peaks (Figure S6A). The relatively
modest effects on gene expression are not surprising because
the exogenous transfection and overexpression of WT and
mutant JARID1B in SUM159PT basal cells may not fully repro-
duce the physiologic differences in their function; protein levels
might be higher than that of endogenous and some transcription
factors required for the expression of luminal genesmay be lack-
ing in SUM159PT cells. Thus, precise understanding of mutant
JARID1B function in HCC2157 cells would require the analysis
of cells following the selective deletion of mutant or wild-type
JARID1B alleles.
Intriguingly, ESRP1, encoding a key regulator of luminal
splicing patterns (Warzecha and Carstens, 2012), was one of
the genes more significantly enriched for mutant than wild-type
JARID1B and its expression increased the most significantly
after mutant JARID1B transfection in SUM159PT cells (Fig-
ure S6A). ESRP1 is also one of themost significantly differentially
expressed genes between luminal and basal breast cancer
cells, and the differences in its endogenous levels between
HCC2157 and other basal-like cell lines were the largest among
all genes analyzed (Figure S6A). These observations led us to
explore the splicing patterns of genes with known luminal-basal
cell-specific variants, such as ENAH and CD44 (Shapiro et al.,
2011), in our RNA-seq data. We found that the HCC2157 basal
cell line expressed the luminal splice variants of all of these
genes (Figure S6B), potentially because of high ESRP1 levels
induced by mutant JARID1B. Correlating with this, transfection
of mutant JARID1B in SUM159PT cells increased the expressionof luminal splice variants for several genes (Figure S6C), further
supporting the functional relevance of mutant JARID1B in
HCC2157 cells.
Interestingly, HCC2157-unique JARID1B peaks did not over-
lap with CTCF in contrast to all JARID1B peaks detected in these
cells (Figure 7E), implying the lack of co-occurrence of the two
factors at the unique sites.We experimentally tested this hypoth-
esis by performing immunoprecipitation for Myc-tagged wild-
type ormutant JARID1B followed byCTCFwestern. Lower levels
of CTCF were detected in mutant JARID1B immunoprecipitates,
potentially implying that mutant JARID1B and CTCF may not be
found in the same protein complexes (Figure 7F). These results
further support the functional relevance of CTCF-JARID1B
interaction and imply that somatic mutations in JARID1B (or
potentially also inCTCF)may alter the composition of these com-
plexes, leading to altered JARID1B function. To explore this, we
investigated H3K4me2 and H3K4me3 signal in HCC2157 cells at
common and HCC2157-unique JARID1B peaks in promoter and
nonpromoter areas, assuming that all ormost of unique binding is
due to the mutant protein. Unique JARID1B promoter peaks had
much lower H3K4me2 and H3K4me3 signal compared to the
common ones, whereas nonpromoters had about the same low
signal for both unique and common sites (Figure 7G). Although
there could bemany potential explanations for these differences,
these data suggest that mutant JARID1B-containing complexes
may have increased HDM activity.
DISCUSSION
Perturbations of cell type-specific transcriptional programs play
key roles in tumorigenesis, in particular, in breast cancer a signif-
icant fraction of recurrently mutated genes encode for transcrip-
tion factors or epigenetic regulators (Polyak and Metzger Filho,
2012). Although therapeutic targeting of aberrant transcriptional
programs has been challenging, the identification of BET bromo-
domain inhibitors as regulators of the MYC oncogene (Delmore
et al., 2011; Filippakopoulos et al., 2010) have reignited interest
in this area. Developing specific inhibitors of chromatin regula-
tors is one of the most active areas of current drug discovery ef-
forts. However, the validation and application of these inhibitors
require the precise understanding of the biochemical and tumor-
igenic function of these epigenetic regulators. Here, we describe
a role of JARID1B in breast cancer and reveal that its chromatin
binding and HDM activity might be modulated by associated
proteins, such as CTCF. Thus, its potential therapeutic targeting
might require a more sophisticated approach than simple inhibi-
tion of enzymatic activity.
Our finding of a nearly complete overlap between JARID1B
binding and H3K4me3 mark seems paradoxical as JARID1B is
a H3K4me3 demethylase. However, similar observations have
been made in two unrelated cell types: human leukemia (Ram
et al., 2011) and mouse ESCs (Schmitz et al., 2011). Thus, it ap-
pears to be a general phenomenon, and it may reflect enzyme-
substrate colocalization as reported for JARID1A (Lopez-Bigas
et al., 2008). Correlating with the preferential binding of JARID1B
to promoters enriched for H3K4me3 and active genes, down-
regulation of JARID1B had only modest effects on global
H3K4me3 and transcript levels, especially in luminal breast can-
cer cells. Thus, it appears that JARID1B is not a strongCancer Cell 25, 762–777, June 16, 2014 ª2014 Elsevier Inc. 771
(legend on next page)
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cific histone H3K4 methylation and transcript levels.
Despite the association of JARID1B binding with actively
transcribed genes, both in luminal and basal-like breast cancer
cells, the promoters and enhancers of luminal-high genes were
significantly enriched for JARID1B binding, whereas no such
enrichment is seen for basal-high genes. Thus, despite the
fact that JARID1B binding is associated with active genes, there
is still a significant luminal-basal difference. These results are in
line with recent observations for other HDMs like KDM4B/C
in ESCs (Das et al., 2014) and also the preferential effects
of BET bromodomain inhibitors on BRD4 binding at ‘‘super-
enhancers’’ and associated genes (Whyte et al., 2013). Thus,
it appears that many chromatin regulators may have a relatively
broad, low-level binding at many sites, implying nonspecific ac-
tion, but a subset of sites with the highest binding signal confer
specificity.
We also found a colocalization between JARID1B and CTCF
that appears to be specific for breast cancer cells (or epithelial
cells) as itwasnot observed in hematopoietic andEScells. Based
on our data, CTCF may modulate JARID1B binding and HDM
activity, but neither of these appears to have a pronounced effect
on gene transcription due to the complex regulation of Pol II at
multiple different levels. Because CTCF with promoter binding
pauses Pol II (Paredes et al., 2013; Shukla et al., 2011),
JARID1B might be recruited to promoters to reduce H3K4me3
level to counteract Pol II accumulation (Li et al., 2007). Knock-
downofCTCF, although releasesPol II pausing, dissociates JAR-
ID1B from the chromatin, and creates muted expression
changes.
The consensus JARID1B binding motif is CG rich, implying
potential modulation by DNA methylation. Indeed, we found
that JARID1B-bound promoters were less methylated, and pro-
moter regions of up and downregulated genes after siJARID1B
transfection displayed significant differences in DNAmethylation
levels. CTCF binding is also inhibited by DNA methylation (Shu-
kla et al., 2011), and JARID1B-CTCF overlapping sites were even
less methylated than those with CTCF-only binding. Based on
our observations that CTCF may modulate JARID1B’s DNA
binding and HDM activity, it is intriguing to speculate that the
combinatorial effects of JARID1B-CTCF and regulators of DNA
and H3K27 methylation work together to establish luminal
epithelial differentiation programs. Correlating with this, CTCF
and KDM6A mutations are commonly found in luminal breast
cancer cells (Ciriello et al., 2013; Ellis et al., 2012).Figure 6. JARID1B-CTCF Interaction
(A) CTCF enrichment around JARID1B peak summits in both MCF7 and SUM15
(B) Examples of JARID1B-CTCF overlap in MCF7 cells based on visualization of
(C) Bar graphs depicting JARID1B and CTCF overlap at promoter and nonpromot
only and JARID1B-CTCF-overlapping sites in nonpromoter and promoter region
Fisher’s exact test).
(D) Immunoblots showing the immunoprecipitation of JARID1B and CTCF in bre
(E) H3K4me3 signal profile around JARID1B peak summit in MCF7 and SUM159
(F) JARID1B, CTCF, and H3K4me3 signal around all promoters inMCF7 and SUM1
The JARID1B and CTCF signal are significantly different between MCF7 and SU
(G) Changes in JARID1B chromatin binding in promoter peaks (left) and nonpromo
JARID1B-CTCF-overlapping sites.
See also Figure S5 and Table S5.The frequent copy number gain and our ChIP-seq and
functional data imply that JARID1B activity may particularly
be important in luminal breast tumors that in general have
better outcome than does basal-like breast cancer. However,
our data also show that high luminal JARID1B activity in ER+
tumors may be associated with endocrine resistance. Further-
more, the expression of a luminal gain-of-function JARID1B
mutant (e.g., K1435R JARID1B in HCC2157 cells) aberrantly
activating some luminal genes in basal breast tumors may
result in less favorable clinical behavior. Correlating with this,
gain of luminal features, such as the increased expression of
CD24, are commonly observed in treatment-resistant distant
metastatic lesions (Shipitsin et al., 2007) and in chemo-
therapy-resistant TNBCs (Almendro et al., 2014). The JARID1B
mutant in HCC2157 cells displayed gain of binding to genomic
loci not detected in other cells expressing the WT protein.
Mutant JARID1B also appears to be associated with different
proteins at these unique sites, and these complexes may
have increased HDM activity compared to those with WT
JARID1B. Thus, the mutation may perturb both chromatin bind-
ing and enzymatic activity. Somatic point mutations in JARID1B
have not been commonly observed in breast and other tumor
types. However, thus far all large-scale sequencing studies
have focused on primary treatment-naive tumors, which may
not reveal mutations associated with metastatic progression
and therapy resistance.
Together, these data imply that JARID1B functions as an
oncoprotein in breast cancer by driving a luminal transcriptional
program. There can be many reasons why cancer cells with
luminal expression patterns may have growth advantage. One
possibility is that such cells may be more resistant to therapeutic
interventions, as has been described inmelanoma (Roesch et al.,
2010, 2013). Our data demonstrating enrichment for cancer
cells with luminal features in neoadjuvant chemotherapy-resis-
tant breast tumors support this hypothesis (Almendro et al.,
2014).
In summary, we describe the detailed molecular characteriza-
tion of the JARID1B H3K4 histone demethylase in breast cancer.
Our data support a key role for JARID1B in luminal cell-specific
gene expression programs and demonstrate that JARID1B is a
luminal lineage-driving oncogene in breast cancer. Furthermore,
as ER+ breast tumors with high JARID1B activity are associated
with worse clinical outcome and resistance to endocrine ther-
apy, therapeutic targeting of JARID1B may be a potential treat-
ment strategy for this disease.9PT cells.
ChIP-seq data for the indicated genes.
er sites in MCF7 and SUM159PT cell lines. The differences between JARID1B-
s are statistically significant, both in MCF7 and SUM159PT cells (p < 2.216,
ast cancer cell lines.
PT cell lines.
59PT cell lines. Gene promoters are ranked by the average signal of H3K4me3.
M159PT cells (p value < 2.216, Wilcoxon test).
ter peaks (right) following transfection of siCTCF in MCF7 cells. Red dots mark
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Figure 7. JARID1B Gain-of-Function Mutation in HCC2157 Cells
(A) Schematic structure of JARID1B gene with exons, functional protein domains, and the location of somatic mutations identified in various human cancer types.
(B) Heatmap of clustering of samples based on the expression of genes associated with HCC2157-unique peaks.
(C)Heatmapshowing thedifferential expressionofa subsetofgenes (top500geneswithhigherexpression inHCC2157cells compared tootherbasal lines)associated
with HCC2157-unique JARID1B peaks. ‘‘Cell line expr’’ indicates transcript levels in HCC2157 cells, and Basal-lumA denotes difference in expression level between
basal and luminal tumors, where blue indicates higher expression in the latter group. Green rectangle highlights luminal genes highly expressed in HCC2157 cells.
(D) ChIP-qPCR analysis of enrichment for HCC2157-unique JARID1B peaks by Myc-tagged wild-type and mutant (K1435R) JARID1B transfected into
SUM159PT cells. * and ** asterisks indicate p < 0.05 and p < 0.001, respectively, whereas error bars mark SD. Inset shows immunoblot analysis of exogenously
expressed Myc-tagged wild-type and K1435R mutant JARID1B in SUM159PT cells.
(E) Degree of enrichment of CTCF binding sites in JARID1B all peaks (left panel) and unique peaks (right panels) in the HCC2157 cell line.
(F) Immunoblots showing the immunoprecipitation of CTCF in wild-type or K1435R JARID1B mutant cells.
(G) Patterns of H3K4me3 and H3K4me2 signal profile around common and HCC2157-unique JARID1B peak summit.
See also Figure S6.
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Detailed procedures are described in the Supplemental Experimental
Procedures.
Breast Cancer Cell Lines
Breast cancer cell lines were obtained from ATCC or generously provided by
Steve Ethier (SUM cell lines; University of Michigan) and cultured following the
provider’s recommendations.
siRNA Transfection, RNA Isolation, and qRT-PCR
siRNAs against JARID1B, CTCF, SMAD4, and TGFBR2 were purchased from
Dharmacon in the form of ONTARGET-plus SMARTpool reagents (L-009899,
L-020165, L-003902, and L-003930, respectively). Individual siRNAs against
JARID1B (LQ-009899) were also purchased and used for the rescue experi-
ments. Transfections of siRNA (15 nM) were performed using DharmaFECT
transfection reagents (Dharmacon) in accordance with the manufacturer’s
protocol. Five days after transfection, total RNA was isolated from cells using
an RNeasy Mini Kit (QIAGEN), following the manufacturer’s protocol. First-
strand cDNA synthesis was carried out using random hexamer oligos and
SuperScript II (Life Technologies). Then cDNA was analyzed by qPCR using
Power SYBR PCR Master Mix and 7500 Real-Time PCR Systems (Applied
Biosystems). Primer sequences are available upon request.
TGFBR Inhibitor Treatment
Cells were seeded in a 96-well plate, and siControl or siJARID1B were trans-
fected. On the next day, TGFBR inhibitor (LY2109761) dissolved in DMSOwas
added into medium at 0, 1, 5, or 10 mM final concentration. DMSO concentra-
tion in culture medium is adjusted to 0.5% final concentration. Two days later,
the culture mediumwas changed to fresh medium containing the inhibitor, and
2 days later cell viability was assessed using CellTiter-Glo (Promega).
Immunoblotting and Coimmunoprecipitation
Cell lysates were prepared 5 days after siRNA transfection. The proteins
resolved in SDS-polyacrylamide gels (4%–12%) were transferred electropho-
retically for 2 hr at 4C to polyvinylidene difluoride membranes by using a
Tris-glycine buffer system. Themembraneswere blockedwith 5%milk powder
in 0.1% Tween20 in PBS (PBS-T) for 1 hr at least, and then the antibodies were
added with 2.5%milk in PBS-T. The antibodies used for immunoblotting were
anti-Jarid1B (HPA027179) from Sigma, anti-Jarid1A (ab78322), anti-H3K4me3
(ab8580), anti-H3K4me1 (ab8895), and anti-Histone H3 (ab1791) from Abcam,
anti-H3K4me2 (07-030) from Millipore, and anti-CTCF (BD612148) from BD
Biosciences. For coimmunoprecipitation, nuclear extract of cell lines was pre-
pared as for theChIP experiments, sheared by passing through syringe needle,
diluted, and treatedwithDNase I. The sampleswere incubatedat 4Covernight
with the JARID1B antibody and then precipitatedwith Dynabeads Protein G for
2 hr. Beadswere washedwith buffer containing 150mMNaCl and 0.5%NP-40
three times and then resuspended in SDS-polyacrylamide gel loading buffer.
Myc-JARID1B Overexpression
N-terminal Myc His-tagged human JARID1B (wild-type and K1435R) expres-
sion constructs in pcDNA3.1 were kindly provided by Dr. Yi Zhang (Harvard
Medical School). JARID1B expression plasmids (15 mg plasmid/plate) were
transfected into cells cultured in a 10 cm dish by Lipofectamine LTX (Life Tech-
nologies). For immunoprecipitation, cells were harvested and lysed 4 days
after transfection. Then exogenous JARID1B was probed with 2.5 mg of anti-
Myc antibody (9E10; Millipore). For gene expression analysis, total RNA was
prepared 4 days after transfection and evaluated by qRT-PCR. For rescue
experiments, 25 ng of JARID1B expression plasmids and 20 nM siRNA were
cotransfected in 96-well plate by jetPRIME transfection reagent (Polyplus).
Cell viability was examined 5 days after transfection.
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